Adding radium-223 to treatment with enzalutamide and a bone-protecting agent improved rPFS and OS in patients with mCRPC and ...

Combining radium-223 with enzalutamide offered a survival benefit in metastatic castration-resistant prostate cancer, but experts questioned its relevance in a shifting treatment landscape.

2024年欧洲肿瘤内科学会（ESMO）将于9月13日至17日在西班牙巴塞罗那以线上线下结合形式举行。作为全球规模最大、学术水平最高、最具权威的临床肿瘤学会议之一，众多专家学者将展示肿瘤学领域的最新研究成果，共同推动肿瘤学科的全球发展。

2024年欧洲肿瘤内科学会年会（2024 ESMO）将于当地时间2024年9月13日至17日在西班牙巴塞罗那正式召开。一直以来，最新突破性摘要（LBA，Late Breaking Abstracts）都是年会中备受瞩目的焦点。同时，鉴于前列腺癌是我国泌尿男生殖系统最常见的恶性肿瘤，本次ESMO大会公布的前列腺癌重磅进展对于我国前列腺癌诊疗实践具有重要参考价值。

This report is a review of recent and emerging trends that promise to make radiation oncology for prostate cancer more ...

Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with ...

Radioligand therapies (RLTs) have received prominent attention from major pharmaceutical companies in treating prostate ...

PEACE-3 trial results reveal that Enzalutamide combined with Radium-223 improves survival outcomes in prostate cancer ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Men with castration-resistant prostate cancer (CRPC) and asymptomatic or mildly symptomatic bone metastases lived ...

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

A wide selection of therapies are available to treat advanced prostate cancer, but the optimal treatment strategy is unknown.